Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes

Hybridoma and Hybridomics

Volumn 23, Issue 2, 2004, Pages 109-120

  Hosokawa, Saiko ^a,c   Tagawa, Toshiaki ^a,c   Niki, Hisae ^a,c   Hirakawa, Yoko ^a,c   Ito, Norihiko ^a,d   Nohga, Katsuhiko ^b   Nagaike, Kazuhiro ^a  

^a MITSUBISHI CHEMICAL CORPORATION   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GAH; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER TISSUE; CELL NUCLEUS INCLUSION BODY; CELL ULTRASTRUCTURE; CELL VIABILITY; CHO CELL; COLON CANCER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SELECTIVITY; EXPRESSION VECTOR; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYBRIDOMA; LYMPH NODE CELL; MALE; MOLECULAR CLONING; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TARGET CELL DESTRUCTION; TISSUE SECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; HYBRIDOMAS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; LYMPH NODES; MICE; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

ANIMALIA; VECTORS;

EID: 2542471645     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685904774129711     Document Type: Article

References (38)

1. Hosokawa S, Muramatsu M, and Nagaike K: Detection of membrane-bound alpha-fetoprotein in human hepatoma cell lines by monoclonal antibody 19F12. Cancer Res 1989;49:361-366.
2. Konno H, Suzuki H, Tadakuma T, Kumai K, Yasuda T, Kubota T, Ohta S, Nagaike K, Hosokawa S, Ishibiki K, Abe O, and Saito K: Antitumor effect of adriamycin entrapped in liposomes conjugated with anti-human alpha-fetoprotein monoclonal antibody. Cancer Res 1987;47:4471-4477.
3. Uyama I, Kumai K, Yasuda T, Tagawa T, Ishibiki K, Kitajima M, and Tadakuma T: Improvement of therapeutic effect by using Fab′ fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes. Jpn J Cancer Res 1994;85:434-440.
4. Mastrobattista E, Koning GA, and Storm G: Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999;40:103-127.
5. Imam A, Drushella MM, Taylor CR, and Tökes ZA: Generation and immunohistological characterization of human monoclonal antibodies to mammary carcinoma cells. Cancer Res 1985;45:263-271.
6. Henderikx P, Kandilogiannaki M, Petrarca C, von Mensdorff-Pouilly S, Hilgers JH, Krambovitis E, Arends JW, and Hoogenboom HR: Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 1998;58:4324-4332.
7. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, and Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-1243.
8. Irie RF, Matsuki T, and Morton DL: Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989;1:786-787.
9. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Ruckle-Lanz H, Reindl L, and Müller-Hermelink HK: Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 1998;5:549-552.
10. Hanna MG, Jr, Haspel MV, McCabe RP, Hurray JH, and Pomato N: Development and application of human monoclonal antibodies. Antibody Immunoconjugates Radiopharm 1991;4:67-75.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
13. Safi F, Schlosser W, Kolb G, and Beger HG: Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106-112.
14. Guo H, Klingmuller D, and Bidlingmaier F: Analysis of serum CYFR21-1 by immunoradiometric assay in patients with non-small cell lung cancer. Lung Cancer 1996;16:113-114.
15. Kreitman RJ, and Pastan I: Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998;31:53-88.
16. Sarti P, Ginobbi P, D'Agostino I, Arancia G, Lendaro E, Molinari A, Ippoliti R, and Citro G: Liposomal targeting of leukaemia HL60 cells induced by transferrin-receptor endocytosis. Biotechnol Appl Biochem 1996;24:269-276.
17. Suzuki S, Inoue K, Hongoh A, Hashimoto Y, and Yamazoe Y: Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br J Cancer 1997;76:83-89.
18. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, and Benz CC: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92:1327-1331.
19. Kirpotin D, Park JW Hong K, Zalipsky S, Li WL, Carter P, Benz CC, and Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry (Mosc) 1997;36:66-75.
20. Vlock DR, Scalise D, Schwartz DR, Richter DE, Krause CJ, Baker SR, and Carey TE: Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration. Cancer Res 1989;49:1361-1365.
21. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
22. Coons AH, and Kaplan MH. Localization of antigen in tissue cells 2. Improvements in a method for the detection of antigen by means of fluorescent antibody. J Exp Med 1950;91:1-13.
23. Liang P, and Pardee AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-971.
24. Harabayashi M, Munakata K, and Nagahari K: Production of a mouse/human chimeric monoclonal antibody to a carcinoembryonic antigen. Mitsubishi Kasei R&D Rev 1991;5:85-91.
25. Mishina M, Kurosaki T, Tobimatsu T, Morimoto Y, Noda M, Yamamoto T, Terao M, Lindstrom J, Takahashi T, Kuno M, and Numa S: Expression of functional acetylcholine receptor from cloned cDNAs. Nature 1984;307:604-608.
26. Traut RR, Bollen A, Sun TT, Hershey JW, Sundberg J, and Pierce LR: Methyl 4-mercaptobutyrimidate as a cleavable cross-linking reagent and its application to the Escherichia coli 30S ribosome. Biochemistry (Mosc) 1973;12:3266-3273.
27. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, and Nagaike K: Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density- dependent manner. Br J Cancer 2003;89:1545-1551.
28. Horan PK, Melnicoff MJ, Jensen BD, and Slezak SE: Fluorescent cell labeling for in vivo and in vitro cell tracking. Methods Cell Biol 1990;33:469-490.
29. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janoff AS, and Perkins WR: Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998;1415:23-40.
30. Gabizon A, and Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54:15-21.
31. Vollmers HP, O'Connor R, Müller J, Kirchner T, and Müller-Hermelink HK: SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 1989;49:2471-2476.
32. Chang HR, Chavoshan B, and Park H: Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells. Dis Colon Rectum 1993;36:1152-1157.
33. Yagyu T, Monden T, Baba M, Tamaki Y, Takeda T, Kobayashi T, Shimano T, Tsuji Y, Matsushita H, and Osawa H: A cancer-reactive human monoclonal antibody derived from a colonic cancer patient treated with local immunotherapy. Jpn J Cancer Res Gann 1993;84:75-82.
34. Metzgar RS, Rodriguez N, Finn OJ, Lan MS, Daasch VN, Fernsten PD, Meyers WC, Sindelar WF, Sandler RS, and Seigler HF: Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci USA 1984;81:5242-5246.
35. Sowa M, Chung YS, Nishimura M, Yoshino H, Maekawa H, Kato Y, Umeyama K, and Kawahara M: An immunohistological study of gastric cancer - with special reference to the expression of carbohydrate antigens and nuclear DNA ploidy patterns. Eur J Surg Oncol 1989;15:307-315.
36. Miles DW, Linehan J, Smith P, and Filipe I: Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors. Br J Cancer 1995;71:1074-1076.
37. Lai I-R, Lee W-J, Huang M-T, and Lin H-H: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology 2002;49:1157-1160.
38. Aamdal S, Fodstad O, Nesland JM, and Pihl A: Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice. Br J Cancer 1985;51:347-356.